Drug Information

Drug General Information
Drug ID
D0T8XB
Former ID
DNCL002831
Drug Name
Anagliptin
Drug Type
Small molecular drug
Indication Type 2 diabetes [ICD9: 250; ICD10:E11] Approved [525047], [551871]
Company
Kowa Research Institute
Structure
Download
2D MOL

3D MOL
Formula
C19H25N7O2
Canonical SMILES
CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCCC3C#N
InChI
1S/C19H25N7O2/c1-13-7-16-21-9-14(11-26(16)24-13)18(28)22-12-19(2,3)23-10-17(27)25-6-4-5-15(25)8-20/h7,9,11,15,23H,4-6,10,12H2,1-3H3,(H,22,28)/t15-/m0/s1
InChIKey
LDXYBEHACFJIEL-HNNXBMFYSA-N
PubChem Compound ID
44513473
PubChem Substance ID
85848072, 97105503, 124490520, 135267036, 136921558, 136963390, 136963399, 198963891, 223680252, 227171520, 252447858
Target and Pathway
Target(s) Dipeptidyl peptidase IV Target Info Modulator [544067]
KEGG Pathway Protein digestion and absorption
NetPath Pathway IL2 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
References
Ref 525047ClinicalTrials.gov (NCT02330406) Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial. U.S. National Institutes of Health.
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 544067Diabetes Treatment. Diabetes Care. 2009 March; 32(3): e25-e30.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.